A Marked Low-Grade Inflammation and a Significant Deterioration in Metabolic Status in First-Episode Schizophrenia: A Five-Year Follow-Up Study.

Parksepp, Madis; Haring, Liina; Kilk, Kalle; Taalberg, Egon; Kangro, Raul; Zilmer, Mihkel; Vasar, Eero

Parksepp, Madis; Haring, Liina; Kilk, Kalle; Taalberg, Egon; Kangro, Raul; Zilmer, Mihkel; Vasar, Eero.

Afiliación

Parksepp M; Institute of Clinical Medicine, University of Tartu, 50417 Tartu, Estonia.
Haring L; Psychiatry Clinic of Viljandi Hospital, 71024 Viljandi, Estonia.
Kilk K; Institute of Clinical Medicine, University of Tartu, 50417 Tartu, Estonia.
Taalberg E; Psychiatry Clinic of Tartu University Hospital, 50417 Tartu, Estonia.
Kangro R; Centre of Excellence for Genomics and Translational Medicine, Institute of Biomedicine and Translational Medicine, Univesignallingrsity of Tartu, 50090 Tartu, Estonia.
Zilmer M; Centre of Excellence for Genomics and Translational Medicine, Institute of Biomedicine and Translational Medicine, Univesignallingrsity of Tartu, 50090 Tartu, Estonia.
Vasar E; Centre of Excellence for Genomics and Translational Medicine, Institute of Biomedicine and Translational Medicine, Univesignallingrsity of Tartu, 50090 Tartu, Estonia.

Metabolites ; 12(10)2022 Oct 17.

Article en En | MEDLINE | ID: mdl-36295885

Palabras clave

acylcarnitines; antipsychotic treatment; beta-oxidation; cytokines; first-episode psychosis; low-grade inflammation; metabolic syndrome; obesity; schizophrenia spectrum disorder

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Revista: Metabolites Año: 2022 Tipo del documento: Article País de afiliación: Estonia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google